Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1
antagonist.
Author(s): Holland C(1), van Drunen C, Denyer J, Smart K, Segboer C, Terreehorst I, Newlands
A, Beerahee M, Fokkens W, Tsitoura DC.
Affiliation(s): Author information:
(1)Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, the
Netherlands.
Publication date & source: 2014, Br J Clin Pharmacol. , 77(5):777-88
AIMS: To assess the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of intranasal SB-705498, a selective TRPV1 antagonist.
METHODS: Two randomized, double-blind, placebo-controlled, clinical studies were
performed: (i) an intranasal SB-705498 first time in human study to examine the
safety and PK of five single escalating doses from 0.5 to 12 mg and of repeat
dosing with 6 mg and 12 mg twice daily for 14 days and (ii) a PD efficacy study
in subjects with non-allergic rhinitis (NAR) to evaluate the effect of 12 mg
intranasal SB-705498 against nasal capsaicin challenge.
RESULTS: Single and repeat dosing with intranasal SB-705498 was safe and well
tolerated. The overall frequency of adverse events was similar for SB-705498 and
placebo and no dose-dependent increase was observed. Administration of SB-705498
resulted in less than dose proportional AUC(0,12 h) and Cmax , while repeat
dosing from day 1 to day 14 led to its accumulation. SB-705498 receptor occupancy
in nasal tissue was estimated to be high (>80%). Administration of 12 mg
SB-705498 to patients with NAR induced a marked reduction in total symptom scores
triggered by nasal capsaicin challenge. Inhibition of rhinorrhoea, nasal
congestion and burning sensation was associated with 2- to 4-fold shift in
capsaicin potency.
CONCLUSIONS: Intranasal SB-705498 has an appropriate safety and PK profile for
development in humans and achieves clinically relevant attenuation of
capsaicin-provoked rhinitis symptoms in patients with NAR. The potential impact
intranasal SB-705498 may have in rhinitis treatment deserves further evaluation.
|